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Abstract: Acute ischemic stroke is a major cause of morbidity and mortality in Europe, North America, and Asia. Its 
treatment has completely changed over the past decade with different interventional approaches, such as intravenous 
trials, intra-arterial trials, combined intravenous/intra-arterial trials, and newer devices to mechanically remove the clot 
from intracranial arteries. Intravenous thrombolysis with tissue plaminogen activator (tPA) within 4.5 hours of symptoms 
onset significantly improved clinical outcomes in patients with acute ischemic stroke. Pharmacological intra-arterial 
thrombolysis has been shown effective until 6 hours after middle cerebral artery occlusion and offers a higher rate of 
recanalization compared with intravenous thrombolysis, whereas combined intravenous/ intra-arterial thrombolysis seems 
to be as safe as isolated intravenous thrombolysis. The more recent advances in reperfusion therapies have been done in 
mechanical embolus disruption or removal. Merci Retriever and Penumbra System have been approved for clot removal 
in brain arteries, but not as a therapeutic modality for acute ischemic stroke since it is no clear whether mechanical 
thrombectomy improves clinical outcome in acute stroke. However, mechanical devices are being used in clinical practice 
for patients who are ineligible for tPA or who have failed to respond to intravenous tPA. We summarize the results of the 
major thrombolytic trials and the latest neurointerventional approaches to ischemic stroke. 
Keywords: Thrombolysis, intra-arterial thrombolysis, mechanical thrombectomy, cardioembolic stroke, stroke subtype.  
  Although stroke treatment has completely changed in the 
last fifteen years, stroke remains an important public health 
concern, since is the third leading cause of death in the USA, 
Canada, Europe and Japan and the primary cause of adult 
disability in these developed countries [1].  
  Intravenous (IV) thrombolysis with tissue plasminogen 
activator (tPA, alteplase) within three hours of symptoms 
onset is the standard of care in the treatment of acute 
ischemic stroke in current clinical practice. Despite of the 
spreading use of IV tPA in different countries and continents 
since 1996, IV thrombolysis has several limitations such as a 
short time window, a low rate of arterial recanalization, a 
substantial risk of intracranial haemorrhage, a moderate 
effect on non-selected patients and numerous exclusion 
criteria or contraindications which lead to a low frequency of 
treated patients [2]. All these facts have contributed to 
develop and study new thrombolytic agents, new routes of 
administration, longer time windows of treatment and 
different mechanical devices to locally remove the thrombus 
in the last decade. 
  Clinical research in this topic has elucidated that 
recanalization of the occluded artery is crucial in ischemic 
stroke treatment. A meta-analysis of more than fifty studies 
that evaluated spontaneous or therapeutic arterial recanali-
zation demonstrated a strong correlation between recanali-
zation and good outcome [3]. Recanalyzed patients had a 
higher probability of favourable outcome (OR, 4.43; 95% CI, 
3.32 to 5.91) and a lower probability of mortality (OR, 0.24;  
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95% CI, 0.16 to 0.35) than non-recanalyzed patients at 90 
days. Other key factor that influences on ischemic stroke 
outcome is time to vessel recanalization. Trials of IV 
thrombolysis [4,5] and also of intra-arterial thrombolysis [6] 
have established that good clinical outcome after successful 
recanalization is time-dependent. Longer times from ische-
mic stroke onset to initiation of treatment are associated with 
less absolute clinical benefit. However, delayed thrombolysis 
has shown to be associated with increased reperfusion/ 
recanalization and subsequent improved outcomes when 
patient selection is based on mismatch concept according to 
multimodal MRI or CT techniques [7,8].  
  Therefore, experimental and clinical research in acute 
ischemic stroke is continuously providing new strategies of 
acute management using pharmacological or interventional 
endovascular modalities and promoting the employ of 
radiological multimodal techniques as a treatment-selection 
tool. This article provides a comprehensive review of the 
systemic and endovascular thrombolytic treatment in acute 
ischemic stroke based on the largest prospective studies and 
randomized clinical trials (RCT) and it also reviews parti-
cular aspects of thrombolysis in cardioembolic stroke 
subtype. 
1. INTRAVENOUS THROMBOLYSIS WITHIN 
THREE HOURS 
  In 1995, the pooled results of two phase III  National 
Institute of Neurological Disorders and Stroke (NINDS) 
tissue plasminogen activator trials, demonstrated that IV tPA 
in acute ischemic stroke was safe and effective when given 
within 3 hours from symptoms onset avoiding patients’ death 
or functionally dependent of one out of seven patients treated 
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to have minimal or no disability at 3 months, symptomatic 
intracranial haemorrhage (sHIC) occurred in 6.4% and 
mortality in 17% of them.  
  Four other phase III IV tPA trials (ECASS 1, ECASS 2, 
ATLANTIS A, and ATLANTIS B), did not show positive 
results and failed in demonstrating the benefit of tPA mainly 
for having enrolled a small number of patients in the under 
3-hour time window. When the analysis was restricted to this 
period, the effect was concordant with the one found in the 
two NINDS trials. Despite this, a positive intention-to-treat 
analysis of pooled data from randomized trials of tPA for 
ischemic stroke was reported by Hacke et al. [5]. The study, 
that included 2,775 patients enrolled in the first 6 IV tPA 
trials, showed that treatment within the first 90 minutes of 
onset increased the odds of a favourable outcome by 2.8 
fold, in the 91 to 180-minute window by 1.6 fold, and in the 
181 to 270-minute window by 1.4 fold, while treatment in 
the 271 to 360-minute window did not improve outcome in a 
statistically significant way. So, the sooner tPA is given to 
patients, the greater the benefit is. This analysis also sugges-
ted that a longer time window was not associated with higher 
rates of mortality or symptomatic cerebral haemorrhage. The 
frequency of parenchymal hematoma was related to age and 
tPA administration, but neither to onset to treatment time nor 
to stroke severity measured by means of the NIHSS score. 
Consequently, the apparent reduction in benefit from tPA at 
later periods does not seem to be explained by an increased 
rate of parenchymal hematoma.  
  The use of tPA for acute ischemic stroke was approved 
by the US Food and Drug Administration (FDA) in 1996 and 
subsequently by regulatory agencies in Canada (1999), South 
America, and Asia. In Europe, the European Medicines 
Agency (EMEA) approved the drug in 2002 under two 
conditions: (1) the implementation of an observational study 
(phase IV) in order to assess the use of tPA in the first 3 
hours of stroke onset in clinical practice; and (2) the 
initiation of the third randomized clinical trial (ECASS III) 
to assess the effect of tPA in the 181 to 270-minute window 
from symptoms onset.  
  The Safe Implementation of Thrombolysis in Stroke-
Monitoring Study (SITS-MOST), a phase IV observational 
study, was started in 2002 and completed in 2007. The study 
included 6,483 patients from 285 different sites in 14 
different countries. Half of them were centres that had not 
participated in any of the ECASS trials or had not enrolled 
more than five patients in the two ECASS trials. Primary 
outcomes were symptomatic intracranial haemorrhage within 
first 24 hours and mortality at 3 months. Secondary outcome 
was functional independence at 3 months (modified Rankin 
Scale, mRS 0-2). Compared to RCT, SITS-MOST study 
replicated the safety and effectiveness of IV alteplase in 
acute ischemic stroke in clinical practice even in poor 
experienced sites [9]. 
  Ultrasound-enhanced systemic thrombolysis has been 
proven in tPA-treated patients in several randomized and 
non-randomized clinical studies [10]. According to the 
CLOTBUST study results, ultrasound leads to an absolute 
20% increase in the rate of MCA recanalization [11]. Any 
recanalization was achieved in 83% of patients treated with 
tPA+ 2-MHz transcranial Doppler compared with 50% of 
patients treated with tPA alone within 2 hours of treatment, 
p<0.001, whereas sustained and complete recanalization at 2 
hours was 38% and 13%, respectively. The sICH frequency 
was 3.8% in both groups. This effect was consistent with a 
non significant trend towards and increased rate of improved 
outcome in comparison with only tPA-treated patients (42% 
versus 29%, p=0.2). A recent meta-analysis of 6 randomized 
and 3 nonrandomized clinical studies of sonothrombolysis 
showed that any diagnostic ultrasound monitoring can at 
least double the chance of early complete arterial recanali-
zation at no increase in the risk of sICH [10]. 
  At the present time, tPA is the only approved drug that 
can lead to a recanalization of occluded vessels and restore 
brain circulation before irreversible damage has happened in 
order to improve the clinical outcome.  
2. INTRAVENOUS THROMBOLYSIS AFTER THREE 
HOURS 
2.1. Intravenous Thrombolysis with Alteplase 3 to 4.5 
Hours After Stroke Onset 
  The second condition by EMEA for tPA approval was 
the initiation of the third European Cooperative Acute Stroke 
Study (ECASS III). This randomized clinical trial assessed 
an extended therapeutic window beyond 3 hours. ECASS III 
has recently shown that patients treated with tPA in the 181 
to 270-minute window had a substantially better chance to 
functional independence (mRS 0, 1) 3 months after treatment 
(52.4% vs 45.2%, OR 1.34; IC 95%, 1.02 to 1.76). Sympto-
matic intracranial haemorrhage occurred in 2.4% of the tPA 
group versus 0.2% of the placebo group, with no significant 
increase in mortality (7.8% versus 8.4%) [12].  
  The efficacy and effectiveness of alteplase in the 3 to 4.5-
hour time window is similar to the approved 3-hour window 
when the drug is used in routine clinical practice. The 
evaluation of the Safe Implementation of Thrombolysis in 
Stroke-International Stroke Thrombolysis Registry (SITS-
ISTR) showed that the likelihood of functional recovery, 
sICH, and mortality was not different between the 664 
patients treated in the 3 to 4.5-hour window and the 11,865 
patients treated within the first 3 hours. The rate of sICH 
following NINDS classification (any haemorrhage associated 
to neurological deterioration) was 8.5% and 8% respectively 
after adjustment for clinical trial prognostic factors [13].  
  ECASS III and SITS-ISTR results confirm the conclu-
sions of the analysis of the pooled data from randomized 
trials of tPA for ischemic stroke [5]: IV alteplase adminis-
tered between 3 to 4.5 hours after symptoms onset is effec-
tive and, despite a higher risk of symptomatic intracranial 
haemorrhage as compared to placebo, this treatment is as 
safe as given within the approved 3-hour window. The 
American Heart Association/American Stroke Association 
(AHA/ASA) guidelines for the administration of tPA 
following acute stroke were revised to expand the window of 
treatment from 3 hours to 4.5 hours in order to provide more 
patients with an opportunity to receive benefit from this 
effective therapy [14]. In Europe the recommendation has 
been approved in the Karolinska Stroke Update Conference 
(November 2008), and will be proposed for its inclusion in 
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(http//www.eso-stroke.org/recommendation.php). This  has 
not yet been FDA neither EMEA approved. 
  It is important to point out that, beyond 4.5 hours after 
stroke onset,  no net therapeutic benefit has been 
demonstrated and a new meta-analysis of clinical trials with 
alteplase including data from ECASSIII suggest a significant 
higher risk of sICH (OR 2.96, IC95%, 1.55-5.66) when 
alteplase is administered in the 4.5 to 6-hour window in 
patients selected according to CT scan criteria [15].  
2.2. Intravenous Thrombolysis within 3 to 9 Hours after 
Stroke Onset in Patients with Salvageable Tissue Selected 
by Multimodal MRI 
  Multiple retrospective observational clinical trials 
support the usefulness of multimodal MRI when selecting 
patients for IV thrombolysis beyond 3 hours of stroke 
symptoms onset. Their main findings have been: (a) MRI 
allows to select safely patients for thrombolytic therapy after 
three hours [16,17]; (b) patients with perfusion- weighted 
MRI (PWI) and diffusion-weighted MRI (DWI) mismatch 
treated with alteplase seem to be more likely to recanalize 
and to have less infarct volume and a better functional 
outcome than patients without mismatch [18-20]; (c) early 
recanalization of occluded artery [21] and early cerebral 
perfusion improvement as measured in PWI-MTT maps due 
to recanalization [22] are the most powerful predictors of 
infarct volume and functional outcome in patients treated 
with tPA over passing baseline parameters like mismatch 
volume. Some observational studies have shown that MRI-
base thrombolysis with alteplase in the 0 to 6-hour window 
is equally or more effective than CT-based thrombolysis 
within 3 hours in clinical trials or in clinical practice [20, 
23].  
  Several placebo-controlled clinical trials have used 
multimodal CT or MRI to identify and select 3 to 9-hour 
post-onset patients who still harbour substantial salvageable 
tissue and are likely to benefit from late IV thrombolytic 
treatment; however, this is not yet validated by a positive 
phase III trial. DIAS-2 results have not confirmed the 
favourable conclusions from the pooled analysis of DIAS 
and DEDAS results [24, 25]. DIAS-2 study showed a similar 
prevalence of favourable outcome in patients treated with 
desmoteplase 90 or 125μg/Kg and placebo group. The sICH 
rate was 4% in desmoteplase group and 0% in placebo group 
and mortality was higher among patients who received 
125μg/Kg (21%) [26]. The possible explanations for those 
neutral results could be related to a less overall stroke 
severity, proximal MCA occlusions rate, and baseline 
volume mismatch compared to DEDAS and DIAS leading to 
higher likelihood of spontaneous recovery in the placebo 
group. Treatment groups were small and mortality in the 
high-dose desmoteplase group seems not to be related with 
the drug as it was not due to a higher rate of sICH. The 
ongoing phase III trial of IV desmoteplase (DIAS-3) that 
selects patients by arterial status should definitely elucidate 
if thrombolysis with IV desmoteplase up to 9 hours of 
symptoms onset is safe and effective (clinicalTrials.gov 
Identifier: NCT00790920). 
  The Echoplanar Imaging Thrombolysis Evaluation Trial 
(EPITHET) is a randomized, double blind and placebo-
controlled clinical trial that attended to test whether alteplase 
given 3-6 hours after stroke onset promoted reperfusion and 
attenuated infarct growth in patients who had a mismatch in 
PWI/ DWI images. Patients were selected by CT scan 
criteria, randomized to tPA or placebo, and, later, and MRI 
was performed (not to select patients for treatment). The trial 
resulted negative for primary endpoint (geometric mean 
infarct growth) but several secondary analyses showed 
significant differences in favour of alteplase (median relative 
infarct growth was smaller and reperfusion was more com-
mon with alteplase than with placebo and was associated 
with less infarct growth) [27]. Alteplase was non-signi-
ficantly associated with better neurological outcome (36% 
VS 21%) but reperfusion demonstrated to be a surrogate 
marker of clinical outcomes independently of recanalization 
[28]. 
  Other none placebo-controlled prospective clinical trials 
also suggest that recanalization window could be longer in 
selected patients based on a penumbral pattern. In an 
analysis of a subset of patients from MERCI trial (mecha-
nical embolectomy up to 8 hours from symptoms onset) 
studied pre-treatment and post-treatment with MRI, Kidwell 
et al. observed that response to treatment was significantly 
better among patients who had a penumbral pattern pre-
treatment. At 3 months, 89% of patients with mismatch and 
recanalization had a mRS 0-2 whereas it was the case of only 
14% of patients without mismatch and recanalization [29]. 
The DEFUSE study (DWI Evolution for Understanding 
Stroke Etiology)
 has confirmed that MRI can safely identify 
patients who can benefit from reperfusion therapies after 3 
hours and those with an unfavourable risk/benefit ratio. The 
authors prospectively treated 74 CT-based patients in the 3 to 
6-hour time window with tPA and performed additional 
multimodal MRI before and after thrombolysis. This study 
provided unique data
 demonstrating that early recanalization 
is associated with both
  reduced infarct growth and better 
clinical outcomes in mismatch
  patients, but not in the 
absence of mismatch [30, 31].  
  A recent meta-analysis of data derived from 502 
mismatch patients thrombolyzed beyond 3 hours (pooled 
from the DIAS, DIAS II, DEDAS, DEFUSE, and EPITHET 
trials) has been published. Their results indicate that reper-
fusion/recanalization is more common amongst patients 
selected according to mismatch imaging who receive throm-
bolytic therapy (OR 3.0; 95% CI 1.6 to 5.8) and reperfusion/ 
recanalization is associated with improved outcomes (OR 
5.2; 95% CI 3 to 9). However, delayed thrombolysis in mis-
match patients did not confirm to improve clinical outcome 
(OR 1.3; 95% CI 0.8 to 2.0) [7]. So, delayed treatment accor-
ding to mismatch selection cannot be widely recommended 
as part of routine care and new prospective phase III trials 
are required to validate the mismatch selection paradigm.  
3. INTRA-ARTERIAL AND COMBINED THROM-
BOLYSIS 
  Intra-arterial (IA) thrombolysis consists in the local 
delivery of thrombolytic agents, at or within the thrombus, 
using neurointerventional techniques. Compared with intra-
venous therapy, IA therapy has the advantage of providing a 
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while minimizing the systemic exposure to drug. It has also 
the potential for greater efficacy with higher recanalization 
rates. This technique also allows the mechanical disruption 
of the clot with the catheter or specific devices during the 
procedure. Disadvantages include additional time required to 
initiate therapy, availability only at specialized centres, and 
mechanical manipulation within potentially injured vessels. 
Combined IA and IV thrombolysis provides the speed of 
initiation of IV and a trend to higher recanalization rates of 
isolated IA thrombolysis. Pro-Urokinase (pro-UK), uro-
kinase (UK) and alteplase are the main thrombolytic agents 
used in this kind of procedures.  
  Intra-arterial or combined thrombolysis has been tested 
only in a few controlled trials. The Prolyse in Acute Cerebral 
Thromboembolism II (PROACT II) study demonstrated the 
safety and efficacy of IA thrombolysis in patients with an 
MCA occlusion [32]. One hundred and eighty subjects were 
randomized within 6 hours of stroke onset to receive 9 mg of 
intra-arterial pro-urokinase (pro-UK) and heparin (n=121) or 
IV heparin alone (n=59). Patients in the pro-UK group had a 
greater recanalization rate (partial or complete: 66% versus 
18%, p=0.001; complete: 19% versus 2%, p=0.004) and a 
better functional outcome defined as a mRS 0-2 at 3 months 
(40 versus 25%, p=0.04) than patients in the control group. 
Although sICH rate was greater in the pro-UK group (10% 
versus 2%, p=0.06), overall mortality rates were similar in 
the two treatment arms (25% versus 27%). The Middle 
Cerebral Artery Embolism Local Fibrinolytic Intervention 
Trial (MELT) investigated IA urokinase up to 6 hours after 
stroke onset in patients with a MCA occlusion (M1 or M2) 
[33]. One hundred and fourteen subjects were randomized to 
placebo or intra-arterial UK until the study was stopped 
when IV alteplase was approved in the 0 to 3-hour window. 
Despite the study was non-positive on its primary end point 
of the proportion of patients with good functional outcome 
(mRS 0-2 at 3 months), a favourable trend was perceived 
(49.1% versus 38.6%, p=0.345). However, for the secondary 
end point of excellent functional outcome (mRS 0-1 at 3 
months), substantial benefits were observed (42.1% vs 
22.8%, p=0.045). A meta-analysis of both IA fibrinolysis 
trials (PROACT and MELT) supported the benefit of IA 
fibrinolytic therapy in MCA occlusion within 6 hours of 
symptoms onset [34].  
  Even though the FDA and international regulatory 
agencies did not approve a stroke labelling for pro-UK with 
a single, small, phase III clinical trial, IA thrombolysis 
therapy is commonly administered as an off-label therapy for 
stroke at tertiary centres within 6 hours of onset in the 
anterior circulation and up to 12-24 hours after onset in the 
posterior circulation. ESO 2008 & AHA/ASA 2007 guide-
lines recommend intra-arterial treatment of acute MCA 
occlusion within a 6-hour time window as an option (Class 
II-I, Level B) and in patients with contraindications to the 
Table I.  Baseline Stroke Severity and Outcome Variables in the Main Endovascular and Intravenous Thrombolytic Trials 
   n  NIHSS Basal  Successful Recanalization 
(TIMI 2-3) 
mRS 0-2 at day 90  90-Day 
Mortality 
sICH 
Intra-arterial thrombolysis            
PROACT II [29]  121  17  66%  40%  25%  10% 
MELT [30]  114  14  74%  49%  5%  9% 
IMS [33]  62  18  56%  43%  16%  6% 
IMS-II [34]  55  19  58%  46%  16%  10% 
Mechanical thrombectomy            
MERCI [38]  141  20  48%
+/60% 28%  44%  8% 
Multi MERCI [39]  164 19  55%
+/68% 36%  34%  10% 
Penumbra [41]  125  18  82%
+ 25%  33%  11% 
Intravenous thrombolysis            
Pooling analysis of IV tPA trials within 6 
hours (tPA) [5] 
1391 11  NA  49%  13%  5-9%* 
Control groups            
PROACT II (control) [29]  59  17  18%  25%  27%  2% 
MELT (control) [30]  57  14  NA  39%  3.5%  2% 
Pooling analysis of IV tPA trials within 6 
hours (placebo) [5] 
1384 11  NA  44%  15%  1.1%* 
sICH: symptomatic intracerebral hemorrhage ; + Device alone; * Parenchymal hematoma type II. tPA: tissue plasminogen activator, mRS: modified Rankin Scale; NIHSS: National 
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use of IV thrombolysis, such as recent surgery (Class II, 
Level C). 
  No RCT have compared IA and IV thrombolysis in acute 
ischemic stroke. Although some indirect data suggest a 
higher rate of recanalization of the IA way, it is no clear 
whether the longer time spent in the IA procedure coun-
terbalance the potential benefit of IA thrombolysis. Com-
bined intravenous and intra-arterial thrombolysis is another 
thrombolytic strategy investigated in several non-controlled 
trials that has the benefit of faster initiation of IV treatment 
followed by rescue IA revascularization in patients who have 
not had a successful recanalization after IV treatment and 
higher recanalization rates than IA approaches. Alteplase 
administered intra-arterially and intravenously was the drug 
used in largest and latest studies in that field. The Emergency 
Management of Stroke Trial (EMS) and the Interventional 
Management of stroke Trial (IMS) demonstrated that the 
combined IV/IA approach had similar rates of mortality and 
sICH compared with subjects of similar severity and age 
treated with IV tPA alone in the NINDS stroke trial [35, 36]. 
IMS study included patients younger than 80 with a NIH 
Stroke Scale 10. Combined IV tPA (0.6mg/kg, 60mg 
maximum over 30 minutes) started within 3 hours of onset 
with additional tPA administered via micro catheter at the 
site of the thrombus (up to a total dose of 22 mg over 2 hours 
or until thrombolysis) was safe (6.3% of sICH in IMS 
compared to 6.6% in tPA treated patients of NINDS) 
although good functional outcome was similar to tPA treated 
patients of NINDS (43% versus 39%). IMS II results have 
been recently published [37]. The IMS II study protocol was 
the same than the IMS trial but, in that case, intra-arterial 
tPA was administered via the EKOS micro-infusion catheter 
or a standard micro-catheter. The EKOS micro infusion 
catheter uses acoustic streaming to increase fluid penetration, 
thus driving the thrombolytic agent into the thrombus. 
Recanalization rate was higher than in IMS I (73% versus 
56%), but there were not statistically significant differences 
with respect to functional outcome at 3 months (46% versus 
43%). IMS III is now under way. This phase III, randomized 
and open label trial is testing standard IV tPA treatment 
alone with combined therapy (lower-dose IV tPA plus one of 
a few intra-arterial treatments) in patients in whom tPA is 
initiated within 3 hours of acute ischemic stroke onset 
(ClinicalTrials.gov Identifier: NCT00359424). 
4. MECHANICAL THROMBOLYSIS 
  Mechanical thrombolysis involves the use of catheters to 
directly deliver a clot-disrupting or retrieval device to a 
thromboembolus that is occluding a cerebral artery. This 
approach can improve the rate and speed of recanalization 
and could decrease the incidence of intracranial haemorrhage 
compared with intra-arterial pharmaceutical lytics. Case 
reports and small case series suggested that the use of 
intravascular devices for clot removal in the endovascular 
treatment of ischemic stroke can be considered for patients 
who are not thrombolytic candidates, such as those that have 
had a recent surgical procedure or are under anticoagulation 
treatment [38, 39].  
  First patients treated as part of the Mechanical Embolus 
Removal in Cerebral Ischemia (MERCI) multicenter safety 
trial were published in 2004 [40]. The thrombus retrieval 
device employed (MERCI retriever) is a flexible nitinol wire 
with coil loops that is used with a micro catheter and a 
balloon-guided catheter. Twenty-eight patients with contra-
indication to IV thrombolysis were included in the trial 
within an 8-hour window. This phase I study showed that 
successful recanalization (TIMI grades 2 or 3) with 
mechanical embolectomy was achieved in 12 (43%) patients 
and with additional intra-arterial tPA in 18 (64%). No 
symptomatic intracranial haemorrhage occurred but overall 
efficacy and safety achieved with the MERCI retrieval 
system were not superior to those occurred with IA Pro-UK 
in the PROACT II study. Full MERCI trial results were 
published in 2005 [41]. This trial provided data about the 
safety and effectiveness of endovascular embolectomy with 
Merci Retriever in restoring vascular patency during an acute 
ischemic stroke and provided an alternative intervention for 
patients ineligible for IV thrombolysis. The device was 
deployed in 141 of 151 patients included in the study and 
additional tPA was administered in 51 patients. Baseline 
median NIHSS score was 20. Recanalization with the device 
was achieved in 68 patients (48%) but additional adjuvant 
therapy (tPA, UK, angioplasty, snare) led to recanalization in 
85 (60%) subjects. The overall of good outcome (mRS  2) 
rate was 27.7%. Symptomatic intracranial haemorrhage was 
observed in 11 of 141 (7.8%) patients and clinical significant 
procedural complications (vascular perforation, intramural 
arterial dissection or embolization of a previously uninvol-
ved territory) occurred in 10 of 141 (7.1%) patients. 
Mortality rate in the 141 patients in whom the device was 
deployed was 44%. Importantly, successful recanalization 
was associated with good neurological outcomes (46% 
versus 10%) and reduced mortality (32% versus 54%) and 
was the strongest predictor of favourable outcome at 3 
months (OR, 12.82; 95% CI 2.95 to 55.75).  
  Based on these results, in 2004, the FDA approved 
the Merci Retrieval System to remove clots from vessels in 
patients experiencing an ischemic stroke ineligible for 
intravenous thrombolytics or as a rescue therapy after 
unsuccessful recanalization with tPA. After that, the Multi 
MERCI trial was designed to further evaluate the safety and 
efficacy of combining IV tPA with mechanical thrombec-
tomy and to test a newer-generation thrombectomy device 
(L5 Retriever) compared to first-generation device [42]. This 
study included patients within 8 hours of stroke onset who 
had either failed to respond to IV tPA or were ineligible for 
IV tPA but were still eligible for IA treatment. Baseline 
median NIHSS score was 19. Twenty-nine percent of 
patients received IV tPA prior to treatment with the Merci 
Retriever (0.6-0.9mg/Kg) and recanalization was achieved in 
55% (90/164) of patients with the device alone and increased 
to 68% (112/164) with combined mechanical and IA 
thrombolytic therapy. Symptomatic intracranial haemorrhage 
occurred in 16 patients (9.8%), 5/45 (10%) of those treated 
with combined use of IV tPA and MERCI retriever and 
11/116 (9.5%) in those that did not receive tPA. Overall, 
clinically significant procedural complications occurred in 
5.5% and mortality in 34%. A favourable outcome, modified 
Rankin score of  2, was seen in 36% (59/164) of patients at 
90 days. The overall rates of recanalization (68%), good 
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improved in comparison with those in the MERCI trial. 
Again, outcomes trended better in those patients in whom the 
vessel opened compared with those in whom it did not with 
lower mortality (25% versus 52%) and higher good clinical 
outcomes (49% versus 9.6%). These results allowed to 
conclude that mechanical thrombectomy after IV tPA seems 
as safe as mechanical thrombectomy alone and that the 
newer generation thrombectomy devices achieves higher 
recanalization rates compared with the first-generation 
devices.  
  A number of mechanical thrombolysis devices have 
entered clinical trials for treatment of acute stroke. The FDA 
approved the Penumbra System in 2007 to open vessels in 
patients with ischemic stroke. The device uses aspiration to 
remove the clot. The initial safety trial included 23 patients 
with cerebral ischemia up to 8-hours after symptoms onset 
[43]. All of the treated vessels (100%) were successfully 
recanalized (TIMI 2 or 3). At 30-day follow-up, 45% of 
patients had a mRS <3 or a 4-point or more NIHSS score 
improvement. Mortality rate was 45% taking into account 
that 70% of the subjects at baseline had either an NIHSS 
score of more than 20 or a basilar occlusion. A study 
assessing the safety and efficacy of the system for 
recanalization of vessels was completed in the United States 
and Europe [44]. The goal was to prove “substantial equiva-
lence” to the MERCI device in opening occluded cerebral 
blood vessels in stroke. The Penumbra System trial treated a 
total of 125 target vessels in 125 patients. Patients must 
present within 8 hour of symptoms onset, with neurological 
deficits as defined by an NIHSS score  8 and an 
angiografically verified occlusion of a large intracranial 
vessel. Patients presenting within 3-hour window not eligible 
for IV tPA or with a persistent vessel occlusion after IV 
thrombolysis could be treated. The baseline median NIHSS 
score was 18. The recanalization rate was 81.6% (TIMI 2 or 
3).  Symptomatic intracranial haemorrhages occurred in 
11.2%. All cause mortality was 32.8% at 90 days with 25% 
of patients achieving a modified Rankin score 2. Similar to 
the MERCI and MultiMERCI trials, good outcome were 
more frequent (29% versus 9%) and mortality rate was lower 
(29% versus 48%) with successful compared with unsuccess-
ful recanalization.  
  In summary, both devices (MERCI retriever and Penum-
bra System) can safely and effectively revascularize large 
intracranial vessels in patients experiencing ischemic stroke 
that present within 8 hours from symptoms onset although 
whether such revascularization leads to a better functional 
outcome compared to medical management alone has not 
been still demonstrated. 
  A systematic review and meta-analysis of different 
studies in which mechanical
  thrombectomy with diverse 
devices have been used in the treatment of ischemic stroke 
was reported in 2008 [45]. The pooled cohort was compared 
with a historical cohort
  matched for sex, age, and NIHSS 
score. The search yielded 114 publications with 298 included 
patients, but only 143 were analyzed with a mean NIHSS 
score of 20. The
 clot was accessible in 85% of the patients. 
Any intracranial haemorrhage occurred
  in 22% of the 
patients. Of 81 patients with concurrent thrombolysis,
 18.5% 
had ICH compared with 27.3% of 66 patients without
 throm-
bolysis (p=0.21). Of the 126 patients with accessible
 clots, 
36% had a good mRS (2) and 29% died, whereas in patients 
with inaccessible clots, 24% had a good mRS and 38% died. 
Factors associated with clinical
  success were younger age 
(p =0.001) and lower NIHSS score at admission to the
 hos-
pital (p=0.001). Compared with a matched cohort,
 patients 
who received mechanical intervention were 14.8 times
 more 
likely to have a long-term good outcome. There were no 
differences is the safety parameters between devices, except 
a trend to higher long-term functional independence with 
snare device.  
  Endovascular therapy as a treatment of acute ischemic 
stroke is under incessantly investigation. Recent prospective 
clinical studies have shown that mechanical approaches 
combined with intra-arterial pharmacological therapy are 
associated with higher recanalization rates than either inter-
vention alone (87.7% combined versus 17.6% intra-arterial 
lytics alone versus 46.2% mechanical alone) in acute internal 
carotid artery terminal occlusion [46], and that delayed 
endovascular recanalization later than 8 hours after symp-
toms onset can be safe and effective in carefully selected 
patients by multimodal MRI/CT techniques [47, 48]. 
  However, the true effect on the clinical outcomes of these 
patients would only be elucidated through a randomized trial. 
The Magnetic Resonance and Recanalization of Stroke Clots 
Using Embolectomy (MR RESCUE) trial is currently testing 
the effects of embolectomy with MERCI Retriever stratified 
by the presence of MRI mismatch versus non-mismatch 
pattern at randomization. This randomized trial funded by 
NINDS compares the mechanical approach with medical 
therapy in the 8-hour window from symptom onset. Partici-
pants are randomized to receive treatment either with the 
Merci Retriever and standard medical care or standard 
medical care alone (clinicalTrials.gov Identifier: NCT 
00094588).  
  No other mechanical thrombolysis devices have received 
FDA clearance besides MERCI Retriever and Penumbra 
System. The EKOS ultrasound device is currently being 
evaluated in the IMS III clinical trial as one of the intra-
arterial interventions in the combined IA/IV group approach. 
The Ultrasound Thrombolytic Infusion Catheter combines 
the use of a distal ultrasound transducer with infusion of a 
thrombolytic agent through the micro catheter. In a pilot 
study, 14 patients with acute stroke (5 anterior circulation 
occlusions and 4 posterior circulation occlusions) were 
treated with IA tPA or rateplase infusion through the EKOS 
micro catheter [49]. The median NIHSS score was 19.5 
(range, 9-27). TIMI grade 2-3 was achieved in 8 (57%) 
subjects in the first hour with an average time to recanali-
zation of 46 minutes. No adverse events related to the 
catheter were registered. Symptomatic ICH rate was 14% 
and mortality rate was 36%. Forty-three percent of patients 
were functionally independent (mRS2) at 90 days follow-
up. As a result, the device was used in 33 of 81 patients 
enrolled in the IMS II trial. Recanalization rate was higher 
when EKOS catheter was employed (24/33, 73%), compared 
to standard micro catheter used in IMS I trial (33/59, 56%).  
  The experience is limited in other mechanical approa-
ches. A few devices have been tested in clinical trials that 224    Current Cardiology Reviews, 2010, Vol. 6, No. 3  Millán et al. 
had to be discontinued, some because of financial consi-
derations and other for safety reasons. A number of mecha-
nical thrombolysis devices (such as Snarelike devices or 
Suction thrombectomy devices) have not still been assessed 
in clinical trials.  
5. THROMBOLYSIS IN CARDIOEMBOLIC STROKE 
  Cardioembolic stroke accounts for one third of all 
ischemic strokes, and atrial fibrillation is the cardiac source 
of emboli in 50% of them [50]. Anticoagulation as a secon-
dary prevention treatment of cardioembolic stroke subtype 
has outstandingly reduced the annual risk of stroke in these 
patients and has completely changed their long-term survival 
[50]. However, acute cardioembolic stroke is associated with 
high morbidity and mortality since it usually causes a severe 
baseline neurological impairment, large infarct volumes and 
an increased risk of hemorrhagic transformation, above all 
when delayed spontaneous or pharmacological-induced 
arterial recanalization occurs [51-53]. 
  The rationale for thrombolysis for acute ischemic stroke 
is recanalization of occluded arteries to re-establish brain 
function by saving tissue at risk. Intravenous thrombolysis 
clinical trials clearly demonstrated a beneficial effect of IV 
tPA when given < 4.5 hours after symptoms onset [4, 5, 12]. 
The efficacy of IV thrombolysis has been established in non-
selected patients because there was no interaction between 
tPA treatment and different baseline variables, suggesting a 
persistent beneficial effect of tPA across all subgroups of 
patients, even for all stroke subtypes [54]. However, these IV 
thrombolysis clinical trials did not monitor presence and 
location of arterial occlusion and recanalization at different 
times after stroke.  
  Arterial recanalization in acute stroke is associated with 
higher probability of long-term good outcome and lower 
probability of mortality [3]. Intravenous thrombolysis and 
pharmacological and mechanical intra-arterial thrombolysis 
have demonstrated to achieve higher and earlier vessel 
recanalization rates than spontaneous recanalization in acute 
stroke [32, 55, 56]. Successful recanalization also depends 
on the site and extent of the thromboembolic occlusion being 
markedly lower in patients with intracranial internal carotid 
occlusion than in those with occlusions of the M1 or M2 
segments of the middle cerebral artery [57, 58]. However, 
there are few data about the influence of the thromboem-
bolus type on arterial recanalization and, in consequence, 
about the response to thrombolytic therapy among different 
stroke subtypes.  
  Experimental studies have revealed that lytic suscep-
tibility and penetration of thrombolytic agents into the 
thrombus depends on the specific structural aspects of clots. 
Old, platelet-rich, and well organized thrombi formed under 
flow conditions have been shown to be more resistant to 
thrombolysis than fresh, fibrin- and red cell-rich clots formed 
under conditions of stasis [59, 60]. In humans, thromboem-
bolic arterial occlusions may originate from various proximal 
sources, including venous sites, mural cardiac thrombi, or 
atherosclerotic lesions within or proximal to the affected 
vessel. Cardiac source of clot might probably represent the 
stroke subtype with more uniform fibrin-rich clots and 
higher efficacy of thrombolysis. A clinical study in 72 
patients with proximal middle cerebral artery occlusion 
treated with IV tPA within 3 hours of onset showed a 
differential pattern of tPA-induced arterial recanalization 
among stroke subtypes [61]. Early recanalization during tPA 
infusion was more frequent in patients with cardioembolic 
stroke (59%) compared with large-vessel disease (8%) and 
undetermined origin (50%). Moreover, recanalization was 
significantly more complete (50% versus 27%) and faster in 
cardioembolic stroke compared with other stroke subtypes. 
Importantly, a graded response in neurological improvement 
at 24 hours and long-term outcome was observed in relation 
to the speed of clot lysis during tPA administration and 
consequently, favourable outcome at 3 months was higher 
(59% versus 40% versus 11%) and mortality rate was lower 
(13% versus 19% versus 41%) in cardioembolic stroke 
patients in comparison with undetermined and large-vessel 
disease stroke, respectively [61]. Middle cerebral artery 
recanalization rate has been also confirmed to be higher in 
cardioembolic stroke in an intra-arterial thrombolysis clinical 
study in which 76 patients were treated within 6 hours of 
symptom onset [51]. Complete recanalization was achieved 
in 83% of cardioembolic and 61% of atherosclerotic strokes 
although in this study poor outcome and mortality (mRS >2) 
were more frequent in cardioembolic stroke (50% versus 
35%), probably for the reason that neurological deficit at 
admission was more severe in cardioembolic (mean NIHSS 
19.7) than in atherothrombotic (mean NIHSS 16.6) subtype 
[51]. The trend to a higher rate of vessel recanalization in 
cardioembolic stroke with thrombolytic therapies might be as 
well explained for low plasma levels of endogenous tPA and 
its inhibitor (plasminogen activator inhibitor-1 or PAI-1) 
since the raise of these markers have been related to 
increased risk of atherothrombotic ischemic events such as 
stroke or myocardial infarction [62]. Nevertheless, tPA 
antigen, PAI-1 antigen, PAI activity and tPA/PAI-1 complex 
levels were significantly higher in ischemic stroke patients in 
comparison with a control group, but no differences were 
found regardless of stroke etiology except for lower levels of 
PAI-1 antigen in cardioembolic stroke in a case-control 
clinical study [63].  
  There are some studies that are not in line with a different 
pattern of recanalization according to stroke subtype. In a 
local intra-arterial thrombolysis study with UK in 62 patients 
with middle cerebral artery or intracranial internal carotid 
occlusion, only the thromboembolus location affected 
arterial recanalization. Neither stroke etiology nor other 
baseline parameters were related to successful recanalization 
[58]. Importantly, within the group of cardioembolic occlu-
sions, recanalization was significantly less when transoeso-
phageal echocardiography showed a cardiac thrombus 
compared with those patients in which did not reveal the 
thrombus, probably explained by the different composition 
and age of the clot [58]. The embolic material is likely to be 
fibrin-rich in patients with atrial or ventricular thrombus, 
whereas in other conditions such as patent foramen ovale, 
right-to-left shunt, venous thrombi or recent onset of 
arrhythmia, clot is supposed to be fresher with higher content 
of platelets and red blood cells leading to an easier recana-
lization with thrombolytic therapies. Histological analysis of 
thromboembolus retrieved by endovascular mechanical 
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carotid artery in 25 patients with acute ischemic stroke 
revealed that most clots (75%) shared architectural features 
of random fibrin-platelet deposits interspersed with linear 
collections of nucleated cells and confined erythrocyte-rich 
regions, being red clots composed uniquely of erythrocytes 
and cholesterol crystals uncommon [64]. In addition, 
cardioembolic and atherosclerotic sources of embolism had 
similar histological components with a high prevalence of a 
fibrin:platelet pattern [64].  
  Hence, it is controversial whether vessel recanalization 
with IV or endovascular thrombolytic therapies depends on 
the characteristics of the clot, and consequently, on the 
stroke subtype [51, 58, 61, 63, 64]. However, results of large 
clinical studies [64] and main randomized clinical trials of 
IV thrombolysis [4, 5, 54] have demonstrated no significant 
difference in final outcome in tPA-treated patients based on 
confirmed stroke mechanism.  
6. CONCLUSIONS 
  Since 1996 after tPA approval, treatment of acute 
ischemic stroke has totally changed. Intravenous throm-
bolysis has demonstrated to be safe and effective up to 4.5 
hours after symptoms onset, however the frequency of 
treated patients is still quite low due to a number of burdens 
and failures in the optimal accomplishment of the treatment. 
Endovascular therapy in acute ischemic stroke has become a 
promising alternative for patients who are ineligible for 
intravenous thrombolysis or have failed in recanalyzing the 
occluded artery. Neurointerventional approaches in the 
treatment of acute ischemic stroke offer higher recanalization 
rates compared with intravenous thrombolysis but it is no 
clear whether improve outcomes. Randomized clinical trials 
are necessary to elucidate the true effect of endovascular 
thrombolysis on clinical outcomes. 
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